Role of DDX3 in the pathogenesis of inflammatory bowel disease
Open Access
- 15 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (70) , 115280-115289
Abstract
Role of DDX3 in the pathogenesis of inflammatory bowel disease Role of DDX3 in the pathogenesis of inflammatory bowel diseaseKeywords
This publication has 50 references indexed in Scilit:
- MMP3 and CXCL1 are potent stromal protein markers of dysplasia–carcinoma transition in sporadic colorectal cancerEuropean Journal Of Cancer Prevention, 2014
- Chemokines in Inflammatory Bowel DiseasesDigestive Diseases, 2010
- Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epitheliumClinical and Experimental Immunology, 2008
- Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseasesNature Reviews Drug Discovery, 2007
- Inflammatory bowel disease: clinical aspects and established and evolving therapiesThe Lancet, 2007
- The fundamental basis of inflammatory bowel diseaseJournal of Clinical Investigation, 2007
- Expression of matrix metalloproteinase-1 and tumor necrosis factor-α in ulcerative colitisWorld Journal of Gastroenterology, 2007
- Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s diseaseGut, 2004
- Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel diseaseClinical and Experimental Immunology, 2000
- Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease.Gut, 1995